Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 32 for your search:
Cancer Type/Condition:
Brain tumor, child: PNET
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Induction Chemotherapy Comprising Vincristine, Etoposide, Cyclophosphamide, and Cisplatin With or Without High-Dose Methotrexate and Leucovorin Calcium Followed by Consolidation Chemotherapy Comprising Carboplatin and Thiotepa and Peripheral Blood Stem Cell Rescue in Pediatric Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 3
Sponsor:
NCI
Protocol IDs:
COG-ACNS0334
, ACNS0334, NCT00336024
2.
Phase III Pilot Study of Induction Chemotherapy Followed by Consolidation Myeloablative Chemotherapy Comprising Thiotepa and Carboplatin With or Without Etoposide and Autologous Hematopoietic Stem Cell Rescue in Pediatric Patients With Previously Untreated Malignant Brain Tumors
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 10 at diagnosis
Sponsor:
Other
Protocol IDs:
CHLA-HEAD-START-III
, CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
3.
Phase III Randomized Study of Standard Chemoradiotherapy With or Without Carboplatin Followed by Standard Maintenance Therapy With or Without Isotretinoin and Continuation Therapy With Isotretinoin Versus No Continuation Therapy in Pediatric Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 21
Sponsor:
NCI
Protocol IDs:
COG-ACNS0332
, ACNS0332, NCT00392327
4.
Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 21 at diagnosis
Sponsor:
NCI, Other
Protocol IDs:
CDR0000367486
, SJCRH-SJMB03, NCT00085202
5.
A Phase I/II Study of the Photon Radiosurgery System
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 32
Sponsor:
Other
Protocol IDs:
CNS 0201
, NCT00179907
6.
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 120
Sponsor:
Other
Protocol IDs:
R01 CA 89395-01
, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
7.
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP23573-07-110
, SUN08-01, NCT00704054
8.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
9.
Phase I/II Study of MET Tyrosine Kinase Inhibitor PF-02341066 in Children With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 21
Sponsor:
NCI
Protocol IDs:
COG-ADVL0912
, ADVL0912, NCT00939770
10.
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 30
Sponsor:
Other
Protocol IDs:
OHSU-5056
, OHSU SOL-08131-L, NCT00983398
11.
Phase II Study of Intrathecal Iodine I 131 Monoclonal Antibody 3F8 in Patients With GD2-Expressing Central Nervous System or Leptomeningeal Neoplasms
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
MSKCC-05122
, NCT00445965
12.
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 21 years
Sponsor:
Other
Protocol IDs:
NYU 05-40 H12853
, PBMTC ONC-032P, NCT00528437
13.
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
3368
, NCT00576537
14.
Antineoplaston Therapy in Treating Children With Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 17 years
Sponsor:
Other
Protocol IDs:
CDR0000066490
, BC-BT-10, NCT00003458
15.
Phase I Study of Photodynamic Therapy With Benzoporphyrin Derivative Monoacid Ring A in Patients With Refractory Brain Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
3 to 70
Sponsor:
Other
Protocol IDs:
MCW-7594
, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
16.
Phase I Study of Intra-Arterial Melphalan and Mannitol in Patients With Central Nervous System Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 months and over
Sponsor:
NCI
Protocol IDs:
OHSU-1299
, OHSU-ONC-98018-L, OHSU-4834, NCT00253721
17.
Phase I Study of AZD2171 in Pediatric Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
PBTC-020
, NCT00326664
18.
Phase I Study of Topotecan Hydrochloride by Convection Enhanced Delivery (Intracerebral Clysis) in Patients With Refractory or Progressive Primary Malignant Brain Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
1 and over
Sponsor:
NCI
Protocol IDs:
CPMC-AAAA-4229
, CPMC-14220, NCT00324844
19.
Phase I Study of Trabectedin in Pediatric Patients With Relapsed or Refractory Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
4 to 16
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0054
, NCT00437047
20.
Phase I Study of Enzastaurin Hydrochloride in Children and Adolescents With Refractory Primary CNS Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
PBTC-023
, PBTC-023, NCT00503724
21.
Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
2007-0370
, NCT00513162
22.
Phase I Study of MK0752 in Young Patients With Recurrent or Refractory CNS Malignancies
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
3 to 21
Sponsor:
NCI
Protocol IDs:
PBTC-024
, PBTC-024, NCI-09-C-0112, NCT00572182
23.
Phase I Study of Total Marrow Irradiation With Helical Tomotherapy Image-Guided Intensity-Modulated Radiotherapy Followed by Alkylator-Intense Conditioning Comprising Busulfan, Melphalan, and Thiotepa and Autologous CD34+ Hematopoietic Progenitor Cell Transplantation in Patients With High-Risk or Relapsed Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
70 and under
Sponsor:
NCI
Protocol IDs:
UMN-2005LS023
, UMN-2005LS023, UMN-MT2004-30, NCT00623077
24.
A Trial of RAD001 and Avastin in Children With Recurrent Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
RADBEV
, NCT00756340
25.
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 months to 23 years
Sponsor:
Other
Protocol IDs:
ACH-CNS-001
, NCT00876993
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
